Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.53 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5255607 | 0.92 | GSK3B (0.52) | GSK3BADORA3ADORA2AADORA2BADORA1 | |
| Hydrochloric Acid SCHEMBL5259095 | 0.91 | GSK3B (0.63) | GSK3B | |
| SCHEMBL6582702 | 0.83 | GSK3B (0.56) | GSK3BINPPL1ADORA2AADORA1 | |
| SCHEMBL4987619 | 0.83 | GSK3B (0.44) | GSK3BSIGMAR1 | |
| SCHEMBL4991291 | 0.78 | GSK3B (0.46) | GSK3B | |
| SCHEMBL4994634 | 0.78 | GSK3B (0.46) | GSK3B | |
| SCHEMBL4996272 | 0.76 | GSK3B (0.48) | GSK3B | |
| SCHEMBL6581578 | 0.76 | GSK3B (0.55) | GSK3BADORA2AADORA1 | |
| SCHEMBL4990655 | 0.75 | GSK3B (0.44) | GSK3BSIGMAR1 | |
| SCHEMBL6584593 | 0.75 | GSK3B (0.72) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1487822-B1 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | GSK3B 205/4885INPPL1 820/4885SIGMAR1 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.